ALAT Recommendations for the Use of Respiratory Vaccines Evidence-Based Clinical Practice Guideline
Article Sidebar
Main Article Content
Abstract
Introduction: Respiratory infections are the leading cause of respiratory disease-related mortality worldwide. Infections caused by Streptococcus pneumoniae, influenza virus, Bordetella pertussis, SARS-CoV-2 and Respiratory Syncytial Virus (RSV) now have safe and effective vaccines available.
This document represents a Clinical Practice Guideline (CPG) by the Latin American Thoracic Association (ALAT), developed through the initiative of the departments of infectious diseases and pediatrics, with the goal of establishing recommendations on respiratory vaccines using the available evidence.
Method: A guideline development group was established, composed of five lead physicians responsible for the overall project. Five working subgroups were created, one for each vaccine, involving invited experts in adult pulmonology, pediatrics, and infectious diseases, who formulated clinical questions. A group of expert methodologists then transformed these clinical questions into PICO questions, with nine questions selected using the DELPHI method. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) system was then used to assess the available evidence.
Results: Recommendations were obtained for the adult and pediatric populations for pneumococcal, influenza, pertussis, COVID-19 and Respiratory Syncytial Virus vaccines based on PICO questions. Additionally, recommendations based on narrative questions related to the use of respiratory vaccines in populations with chronic respiratory diseases such as asthma, COPD, and pulmonary fibrosis were included.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
World Health Organization. Global health estimate, the top 10 causes of death [Internet]. 2020 [Consultado 8 jun 2024]. Disponible en: http://www.who.int/news-room/fact-sheets/detail/the-top10-causes-of-death
Wang X, Li Y, O’Brien KL et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. Lancet Glob Health 2020;8(4):e497–510. Doi: 10.1016/S2214-109X(19)30545-5.
GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 2018;18(11):1191–210. Doi: 10.1016/S1473-3099(18)30310-4.
Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2(Suppl 2):S27-72. Doi: 10.1086/511159.
Simon S, Joean O, Welte T, Rademacher J. The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus. Eur Respir Rev 2023;32(169). Doi: 10.1183/16000617.0034-2023.
Organización Panamericana de la Salud. Inmunización en las Américas, Resumen 2019 [Internet]. 2019 [Consultado 8 jun]. Disponible en: https://www.paho.org/es/documentos/inmunizacion-americas-resumen-2019
Guyatt GH, Oxman AD, Kunz R et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011;64(4):395–400.
Miravitlles M, Tonia T, Rigau D et al. New era for European Respiratory Society clinical practice guidelines: joining efficiency and high methodological standards. Eur Respir J 2018;51(3). Doi: 10.1183/13993003.00221-2018.
Joos G, Bush A, Burghuber OC et al. Taken to task: what is and is not an appropriate response to an ERS guidelines task force? Eur Respir J 2017;50(1). Doi: 10.1183/13993003.00952-2017.
Skaarup KG, Lassen MCH, Modin D et al. The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials. J Infect 2024;89(1):106187.
Riccò M, Cascio A, Corrado S et al. Efficacy of Respiratory Syncytial Virus Vaccination to Prevent Lower Respiratory Tract Illness in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Vaccines (Basel) 2024;12(5).
Glasziou PP, Del Mar C, Salisbury J. Evidence-based Medicine Workbook. 1st ed. BMJ Books; 2003.
Guyatt G, Gutterman D, Baumann MH et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest 2006;129(1):174–81. Doi: 10.1378/chest.129.1.174.
Palekar RS, Rolfes MA, Arriola CS et al. Burden of influenza-associated respiratory hospitalizations in the Americas, 2010-2015. PLoS ONE 2019;14(9):e0221479. Doi: 10.1371/journal.pone.0221479.
World Health Organization. International travel and death. Influenza seasonal [Internet]. [Consultado 19 jun 2024]. Disponible en: http:// www.who.int/ith/diseases/influenza seasonal/en/
Gentile A, Paget J, Bellei N et al. Influenza in Latin America: A report from the Global Influenza Initiative (GII). Vaccine 2019;37(20):2670–8. Doi: 10.1016/j.vaccine.2019.03.081.
Thompson WW, Weintraub E, Dhankhar P et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respi Viruses 2009;3(1):37–49.
World Health Organization. Gripe (estacional) [Internet]. 2023 [Consultado 19 jun 2024]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/influenza-(seasonal)
Pan American Health Organization. Influenza, SARS-CoV-2, VSR y otros virus respiratorios [Internet]. [Consultado 19 jun 2024]. Disponible en: https://www.paho.org/es/temas/influenza-sars-cov-2-vsr-otros-virus-respiratorios
Nair H, Brooks WA, Katz M et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011;378(9807):1917–30. Doi: 10.1016/S0140-6736(11)61051-9.
Wei JS. How lethal is SARS-CoV-2 pneumonia when compared with respiratory syncytial virus and influenza in young children? Aust J Gen Pract 2020;49(10):683–6.
Wang X, Li Y, Mei X, Bushe E, Campbell H, Nair H. Global hospital admissions and in-hospital mortality associated with all-cause and virus-specific acute lower respiratory infections in children and adolescents aged 5-19 years between 1995 and 2019: a systematic review and modelling study. BMJ Glob Health 2021;6(7):e006014. Doi: 10.1136/bmjgh-2021-006014.
Shang M, Blanton L, Brammer L, Olsen SJ, Fry AM. Influenza-Associated Pediatric Deaths in the United States, 2010-2016. Pediatrics 2018;141(4):e20172918. Doi: 10.1542/peds.2017-2918.
Otero-Barrós MT, Durán-Parrondo C. Systematic influenza vaccination in the pediatric population. An Pediatr (Barc) 2023;98(1):1–2. Doi: 10.1016/j.anpede.2022.11.003.
Kim H, Webster RG, Webby RJ. Influenza Virus: Dealing with a Drifting and Shifting Pathogen. Viral Immunol 2018;31(2):174–83.
Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2018;2(2):CD004879.
Blyth CC, Fathima P, Pavlos R et al. Influenza vaccination in Western Australian children: Exploring the health benefits and cost savings of increased vaccine coverage in children. Vaccine X 2023;15:100399. Doi: 10.1016/j.jvacx.2023.100399
Escandell Rico FM, Pérez Fernández L. Efficacy and safety of pediatric flu vaccination: a systematic review. Rev Esp Quimioter 2024;37(1):43–51.
Antonova EN, Rycroft CE, Ambrose CS, Heikkinen T, Principi N. Burden of paediatric influenza in Western Europe: a systematic review. BMC Public Health 2012;12:968. Doi: 10.1186/1471-2458-12-968.
Kopsaftis Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2018;6(6):CD002733.
Mulpuru S, Li L, Ye L et al. Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD. Chest 2019;155(1):69–78. Doi: 10.1016/j.chest.2018.10.044.
Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 2013;2013(2):CD000364.
Vasileiou E, Sheikh A, Butler C et al. Effectiveness of Influenza Vaccines in Asthma: A Systematic Review and Meta-Analysis. Clin Infect Dis 2017;65(8):1388–95. Doi: 10.1093/cid/cix524.
Marijic P, Schwarzkopf L, Maier W, Trudzinski F, Schwettmann L, Kreuter M. Effects of Influenza Vaccination in Patients with Interstitial Lung Diseases: An Epidemiological Claims Data Analysis. Ann Am Thorac Soc 2022;19(9):1479–88. Doi: 10.1513/AnnalsATS.202112-1359OC.
Lai J-J, Lin C, Ho C-L, Chen P-H, Lee C-H. Alternative-Dose versus Standard-Dose Trivalent Influenza Vaccines for Immunocompromised Patients: A Meta-Analysis of Randomised Control Trials. J Clin Med 2019;8(5):590. Doi: 10.3390/jcm8050590.
Lee JKH, Lam GKL, Shin T, Samson SI, Greenberg DP, Chit A. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis. Vaccine 2021;39(1):A24–35.
Lee JKH, Lam GKL, Yin JK, Loiacono MM, Samson SI. High-dose influenza vaccine in older adults by age and seasonal characteristics: Systematic review and meta-analysis update. Vaccine X 2023;14:100327.
DiazGranados CA, Dunning AJ, Kimmel M et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014;371(7):635–45. Doi: 10.1056/NEJMoa1315727.
Thomas LD, Batarseh E, Hamdan L et al. Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients. Clin Infect Dis 2023;77(12):1723–32. Doi: 10.1093/cid/ciad458
Mombelli M, Rettby N, Perreau M, Pascual M, Pantaleo G, Manuel O. Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial. Vaccine 2018;36(41):6163–9.
Vardeny O, Kim K, Udell JA et al. Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. JAMA 2021;325(1):39–49. Doi: 10.1001/jama.2020.23649.
Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts. J Med Virol 2022;94(4):1294–9.
Chatterjee B, Thakur SS. Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. Expert Rev Vaccines 2022;21(1):47–67.
Rubin R. This Fall’s COVID-19 Vaccines Will Target Omicron XBB Subvariants, but Who Needs Them Remains to Be Seen. JAMA 2023;330(4):299–301. Doi: 10.1001/jama.2023.10053.
World Health Organization. COVID-19 epidemiological update – 16 February 2024 [Internet]. 2024 [Consultado 15 mar 2024]. Disponible en: https://www.who.int/publications/m/item/covid-19-epidemiological-update-16-february-2024
Barros-Martins J, Hammerschmidt SI, Cossmann A et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med 2021;27(9):1525–9.
Stankov MV, Hoffmann M, Gutierrez Jauregui R et al. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination. Lancet Infect Dis 2024;24(1):e1–3. Doi: 10.1016/S1473-3099(23)00690-4.
Chalkias S, McGhee N, Whatley JL et al. Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines. J Infect Dis 2024;230(2):e279-e286. Doi: 10.1093/infdis/jiae067.
Harris DA, Hayes KN, Zullo AR et al. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults. JAMA Netw Open 2023;6(8):e2326852.
de Sire A, Moggio L, Marotta N et al. Impact of Rehabilitation on Fatigue in Post-COVID-19 Patients: A Systematic Review and Meta-Analysis. Appl Sci 2022;12(17):8593.
World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [Internet]. 2021 [Consultado 6 nov 2023]. Disponible en: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
Kavanagh KT, Cormier LE, Pontus C, Bergman A, Webley W. Long COVID’s Impact on Patients, Workers, & Society: A review. Medicine (Baltimore) 2024;103(12):e37502.
Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: An overview. Diabetes Metab Syndr 2021;15(3):869–75.
Watanabe A, Iwagami M, Yasuhara J, Takagi H, Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine 2023;41(11):1783–90. Doi: 10.1016/j.vaccine.2023.02.008.
Gao P, Liu J, Liu M. Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2022;19(19): 12422. Doi: 10.3390/ijerph191912422.
Ceban F, Kulzhabayeva D, Rodrigues NB et al. COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis. Brain Behav Immun 2023;111:211–29. Doi: 10.1016/j.bbi.2023.03.022
Marra AR, Kobayashi T, Suzuki H et al. The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post-COVID-19 conditions: A systematic literature review and meta-analysis. Antimicrob Steward Healthc Epidemiol 2022;2(1):e192. Doi: 10.1017/ash.2022.336.
Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med 2023;2(1):e000385. Doi: 10.1136/bmjmed-2022-000385.
Notarte KI, Catahay JA, Velasco JV et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine 2022;53:101624.
Tsampasian V, Elghazaly H, Chattopadhyay R et al. Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis. JAMA Intern Med 2023;183(6):566–80. Doi: 10.1001/jamainternmed.2023.0750.
Lundberg-Morris L, Leach S, Xu Y et al. Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study. BMJ 2023;383:e076990. Doi: 10.1136/bmj-2023-076990.
Asadi-Pooya AA, Nemati M, Shahisavandi M et al. How does COVID-19 vaccination affect long-COVID symptoms? PLoS ONE 2024;19(2):e0296680. Doi: 10.1371/journal.pone.0296680.
Murphy WJ, Longo DL. A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination. N Engl J Med 2022;386(4):394–6. Doi: 10.1056/NEJMcibr2113694.
Couzin-Frankel J, Vogel G. Vaccines may cause rare, Long Covid-like symptoms. Science 2022;375(6579):364–6.
Antonelli M, Penfold RS, Merino J et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2022;22(1):43–55. Doi: 10.1016/S1473-3099(21)00460-6.
Ayoubkhani D, Bermingham C, Pouwels KB et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ 2022;377:e069676. Doi: https://doi.org/10.1136/bmj-2021-069676
Peghin M, De Martino M, Palese A et al. Post-COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients. Clin Microbiol Infect 2022;28(8):1140–8. Doi: 10.1016/j.cmi.2022.03.016.
Nayyerabadi M, Fourcade L, Joshi SA et al. Vaccination after developing long COVID: Impact on clinical presentation, viral persistence, and immune responses. Int J Infect Dis 2023;136:136–45. Doi: 10.1016/j.ijid.2023.09.006.
Fernández-de-Las-Peñas C, Ortega-Santiago R, Fuensalida-Novo S, Martín-Guerrero JD, Pellicer-Valero OJ, Torres-Macho J. Differences in Long-COVID Symptoms between Vaccinated and Non-Vaccinated (BNT162b2 Vaccine) Hospitalized COVID-19 Survivors Infected with the Delta Variant. Vaccines (Basel) 2022;10(9):1481. Doi: 10.3390/vaccines10091481.
Wynberg E, Han AX, Boyd A et al. The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study. Vaccine 2022;40(32):4424–31. Doi: 10.1016/j.vaccine.2022.05.090.
Arjun MC, Singh AK, Pal D et al. Characteristics and predictors of Long COVID among diagnosed cases of COVID-19. PLoS ONE 2022;17(12):e0278825. Doi: 10.1371/journal.pone.0278825.
Mateu L, Tebe C, Loste C et al. Determinants of the onset and prognosis of the post-COVID-19 condition: a 2-year prospective observational cohort study. Lancet Reg Health Eur 2023;33:100724. Doi: 10.1016/j.lanepe.2023.100724.
Hall E, Wodi AP, Hamborsky J. Pneumococcal disease. En: Centers for Disease Control and Prevention, editor. Epidemiology and Prevention of Vaccine-Preventable Diseases. Washington, D.C: Public Health Foundation, 2021; pp. 255–72.
WHO position paper. 23-valent pneumococcal polysaccharide vaccine. Wkly Epidemiol Rec 2008;83(42):373–84.
Giannella M, Pinilla B, Capdevila JA et al. Pneumonia treated in the internal medicine department: focus on healthcare-associated pneumonia. Clin Microbiol Infect 2012;18(8):786–94. Doi: 10.1111/j.1469-0691.2011.03757.x.
Dransfield MT, Harnden S, Burton RL et al. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis 2012;55(5):e35-44. Doi: 10.1093/cid/cis513
Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61(40):816–9.
Chidiac C. Pneumococcal infections and adult with risk factors. Med Mal Infect 2012;42(10):517–24.
Chilson E, Scott DA, Schmoele-Thoma B, Watson W, Moran MM, Isturiz R. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence. Hum Vaccin Immunother 2020;16(11):2758–72. Doi: 10.1080/21645515.2020.1735224
Nagra D, Bechman K, Adas M et al. A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis. Vaccines (Basel) 2023;11(11):1680. Doi: 10.3390/vaccines11111680
van Aalst M, Langedijk AC, Spijker R, de Bree GJ, Grobusch MP, Goorhuis A. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis. Vaccine 2018;36(39):5832–45. Doi: 10.1016/j.vaccine.2018.07.039.
Sprenger R, Häckl D, Kossack N, Schiffner-Rohe J, Wohlleben J, von Eiff C. Pneumococcal vaccination rates in immunocompromised patients in Germany: A retrospective cohort study to assess sequential vaccination rates and changes over time. PLoS ONE 2022;17(3):e0265433. Doi: 10.1371/journal.pone.0265433
Garcia Garrido HM, Vollaard A, D’Haens GR et al. Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy. Vaccines (Basel) 2022;10(5):795. Doi: 10.3390/vaccines10050795.
Hesselstrand R, Nagel J, Saxne T, Geborek P, Skattum L, Kapetanovic MC. Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis. Rheumatology (Oxford) 2018;57(4):625–30. Doi: 10.1093/rheumatology/kex471.
Choi W, Kim JG, Beom S-H et al. Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial. Cancer Res Treat 2020;52(1):246–53. Doi: 10.4143/crt.2019.189.
Essink B, Sabharwal C, Cannon K et al. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years. Clin Infect Dis 2022;75(3):390–8. Doi: 10.1093/cid/ciab990.
Hurley D, Griffin C, Young M et al. Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age. Clin Infect Dis 2021;73(7):e1489–97. Doi: 10.1093/cid/ciaa1045.
Klein NP, Peyrani P, Yacisin K et al. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine 2021;39(38):5428–35. Doi: 10.1016/j.vaccine.2021.07.004.
Sabharwal C, Sundaraiyer V, Peng Y et al. Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease. Hum Vaccin Immunother 2022;18(6):2126253. Doi: 10.1080/21645515.2022.2126253.
Mt-Isa S, Abderhalden LA, Musey L, Weiss T. Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20. Expert Rev Vaccines 2022;21(1):115–23. Doi: 10.1080/14760584.2021.1994858.
Kühne F, Achtert K, Püschner F et al. Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany. Expert Rev Vaccines 2023;22(1):921–32. Doi: 10.1080/14760584.2023.2262575.
Mendes D, Averin A, Atwood M et al. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert Rev Pharmacoecon Outcomes Res 2022;22(8):1285–95. Doi: 10.1080/14737167.2022.2134120.
Cantarero D, Ocaña D, Onieva-García MÁ, Rodríguez-García J, Gálvez P, Méndez C, et al. Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain. Vaccine 2023;41(36):5342–9. Doi: 10.1016/j.vaccine.2023.07.016.
Marbaix S, Mignon A, Taelman A, Averin A, Atwood M, Vietri J. Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults. Expert Rev Vaccines 2023;22(1):1008–21. Doi: 10.1080/14760584.2023.2273892.
World Health Organization. Pertussis vaccines: WHO position paper [Internet]. 2015 [Consultado 6 sept 2023]. Disponible en: https://www.who.int/publications/i/item/WHO-WER9035
Quinn HE, McIntyre PB. Pertussis epidemiology in Australia over the decade 1995-2005--trends by region and age group. Commun Dis Intell Q Rep 2007;31(2):205–15.
Kandeil W, Atanasov P, Avramioti D, Fu J, Demarteau N, Li X. The burden of pertussis in older adults: what is the role of vaccination? A systematic literature review. Expert Rev Vaccines 2019;18(5):439–55. Doi: 10.1080/14760584.2019.1588727.
De Serres G, Shadmani R, Duval B et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000;182(1):174–9. Doi: 10.1086/315648.
McGuiness CB, Hill J, Fonseca E, Hess G, Hitchcock W, Krishnarajah G. The disease burden of pertussis in adults 50 years old and older in the United States: a retrospective study. BMC Infect Dis 2013;13:32. Doi: 10.1186/1471-2334-13-32
van Hoek AJ, Campbell H, Andrews N, Vasconcelos M, Amirthalingam G, Miller E. The burden of disease and health care use among pertussis cases in school aged children and adults in England and Wales; a patient survey. PLoS ONE 2014;9(11):e111807. Doi: 10.1371/journal.pone.0111807
Aris E, Harrington L, Bhavsar A et al. Burden of pertussis in COPD: A retrospective database study in england. COPD 2021;18(2):157–69. Doi: 10.1080/15412555.2021.1899155.
Walker JL, Rentsch CT, McDonald HI et al. Social determinants of pertussis and influenza vaccine uptake in pregnancy: a national cohort study in England using electronic health records. BMJ Open 2021;11(6):e046545. Doi: 10.1136/bmjopen-2020-046545.
Pelullo CP, Della Polla G, Napolitano F, Di Giuseppe G, Angelillo IF. Healthcare Workers’ Knowledge, Attitudes, and Practices about Vaccinations: A Cross-Sectional Study in Italy. Vaccines (Basel) 2020;8(2):148. Doi: 10.3390/vaccines8020148.
Kolobova I, Nyaku MK, Karakusevic A, Bridge D, Fotheringham I, O’Brien M. Vaccine uptake and barriers to vaccination among at-risk adult populations in the US. Hum Vaccin Immunother 2022;18(5):2055422.
Macina D, Evans KE. Bordetella pertussis in School-Age Children, Adolescents and Adults: A Systematic Review of Epidemiology and Mortality in Europe. Infect Dis Ther 2021;10(4):2071–118. Doi: 10.1007/s40121-021-00520-9.
US Center for Disease Control and Prevention (CDC). Pertussis (Whooping Cough) (Bordetella pertussis) 2020 Case Definition [Internet]. 2021 [Consultado 2 sept 2023]. Disponible en: https://ndc.services.cdc.gov/case-definitions/pertussis-2020/
Xu J, Liu S, Liu Q et al. The effectiveness and safety of pertussis booster vaccination for adolescents and adults: A systematic review and meta-analysis. Medicine (Baltimore) 2019;98(16):e15281. Doi: 10.1097/MD.0000000000015281.
Halperin SA, Donovan C, Marshall GS et al. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. J Pediatric Infect Dis Soc 2019;8(2):105–14. Doi: 10.1093/jpids/pix113.
Asatryan A, Meyer N, Scherbakov M et al. Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study. Hum Vaccin Immunother 2021;17(3):723–30.
Versteegen P, Barkoff A-M, Valente Pinto M et al. Memory B cell activation induced by pertussis booster vaccination in four age groups of three countries. Front Immunol 2022;13:864674. Doi: 10.3389/fimmu.2022.864674.
Pool V, Tomovici A, Johnson DR, Greenberg DP, Decker MD. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA. Vaccine 2018;36(17):2282–7. Doi: 10.1016/j.vaccine.2018.03.029.
Liu BC, He W-Q, Newall AT et al. Effectiveness of Acellular Pertussis Vaccine in Older Adults: Nested Matched Case-control Study. Clin Infect Dis 2020;71(2):340–50. Doi: 10.1093/cid/ciz821.
Cho B-H, Acosta AM, Leidner AJ, Faulkner AE, Zhou F. Tetanus, diphtheria and acellular pertussis (Tdap) vaccine for prevention of pertussis among adults aged 19 years and older in the United States: A cost-effectiveness analysis. Prev Med 2020;134:106066. Doi: 10.1016/j.ypmed.2020.106066.
Carvajal JJ, Avellaneda AM, Salazar-Ardiles C, Maya JE, Kalergis AM, Lay MK. Host components contributing to respiratory syncytial virus pathogenesis. Front Immunol 2019;10:2152.
Paris E, Daza P, Tapia L et al. Strategies and recommendations to face respiratory syncytial virus disease in 2024. Andes Pediatr 2024;95(1):17–23. Doi:10.32641/andespediatr.v95i1.5055
Young M, Smitherman L. Socioeconomic impact of RSV hospitalization. Infect Dis Ther 2021;10(1):35–45. Doi: 10.1007/s40121-020-00390-7.
Mazur NI, Löwensteyn YN, Willemsen JE et al. Global Respiratory Syncytial Virus-Related Infant Community Deaths. Clin Infect Dis 2021;73(3):S229–37. Doi: 10.1093/cid/ciab528.
Young J. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir Med 2002;96(B):S31-5. Doi: 10.1053/rmed.2002.1298.
Bohmwald K, Espinoza JA, Rey-Jurado E, Gómez RS, González PA, Bueno SM, et al. Human respiratory syncytial virus: infection and pathology. Semin Respir Crit Care Med 2016;37(4):522–37. Doi: 10.1055/s-0036-1584799.
Bukreyev A, Yang L, Fricke J et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 2008;82(24):12191–204. Doi: 10.1128/JVI.01604-08.
Kaler J, Hussain A, Patel K, Hernandez T, Ray S. Respiratory syncytial virus: A comprehensive review of transmission, pathophysiology, and manifestation. Cureus 2023;15(3):e36342.
Quinn LA, Hirani SH, Williams TC, Sinha IP. Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim? Breathe (Sheff) 2021;17(4):210110. Doi: 10.1183/20734735.0110-2021
Mazur NI, Terstappen J, Baral R et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis 2023;23(1):e2–21. Doi: 10.1016/S1473-3099(22)00291-2.
Ma J, Chen L, Tang S, Shi Y. Efficacy and safety of respiratory syncytial virus vaccination during pregnancy to prevent lower respiratory tract illness in newborns and infants: a systematic review and meta-analysis of randomized controlled trials. Front Pediatr 2023;11:1260740. Doi: 10.3389/fped.2023.1260740
Mapindra MP, Mahindra MP, McNamara P, Semple MG, Clark H, Madsen J. Respiratory Syncytial Virus Maternal Vaccination in Infants below 6 Months of Age: Meta-Analysis of Safety, Immunogenicity, and Efficacy. Neonatology 2024;121(3):271-282. Doi: 10.1159/000536031.
Falsey AR. Respiratory syncytial virus infection in adults. Semin Respir Crit Care Med 2007;28(2):171–81. Doi: 10.1055/s-2007-976489.
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352(17):1749–59. Doi: 10.1056/NEJMoa043951.
Bosco E, van Aalst R, McConeghy KW et al. Estimated Cardiorespiratory Hospitalizations Attributable to Influenza and Respiratory Syncytial Virus Among Long-term Care Facility Residents. JAMA Netw Open 2021;4(6):e2111806. Doi: 10.1001/jamanetworkopen.2021.11806.
Papi A, Ison MG, Langley JM et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med 2023;388(7):595–608. Doi: 10.1056/NEJMoa2209604.
Walsh EE, Pérez Marc G, Zareba AM et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 2023;388(16):1465–77. Doi: 10.1056/NEJMoa2213836.
Wilson E, Goswami J, Baqui AH et al. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. N Engl J Med 2023;389(24):2233–44. Doi: 10.1056/NEJMoa2307079.
Falsey AR, Williams K, Gymnopoulou E et al. Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults. N Engl J Med 2023;388(7):609–20. Doi: 10.1056/NEJMoa2207566.
Falloon J, Yu J, Esser MT et al. An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults. J Infect Dis 2017;216(11):1362–70. Doi: 10.1093/infdis/jix503.
Ison MG, Papi A, Athan E et al. Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (rsvpref3 OA) in older adults over 2 RSV seasons. Clin Infect Dis 2024;78(6):1732–44. Doi: 10.1093/cid/ciae010.
Feldman RG, Antonelli-Incalzi R, Steenackers K et al. Respiratory syncytial virus prefusion F protein vaccine is efficacious in older adults with underlying medical conditions. Clin Infect Dis 2024;78(1):202–9. Doi: 10.1093/cid/ciad471.
US Center for Disease Control and Prevention (CDC). Adult Immunization Schedule by Age [Internet]. 2024 [Consultado 3 jul 2024]. Disponible en: https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html
Wongsurakiat P, Maranetra KN, Wasi C, Kositanont U, Dejsomritrutai W, Charoenratanakul S. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004;125(6):2011–20. Doi: 10.1378/chest.125.6.2011.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention [Internet]. 2024 [Consultado 3 jul 2024]. Disponible en: https://ginasthma.org/2024-report/
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease [Internet]. 2024 [Consultado 4 jul 2024]. Disponible en: https://goldcopd.org/2024-gold-report/
Montes de Oca M, López Varela MV, Acuña A et al. ALAT-2014 Chronic Obstructive Pulmonary Disease (COPD) Clinical Practice Guidelines: questions and answers. Arch Bronconeumol 2015;51(8):403–16. Doi: 10.1016/j.arbres.2014.11.017.
Alfageme I, Vazquez R, Reyes N et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006;61(3):189–95. Doi: 10.1136/thx.2005.043323.
Sheikh A, Alves B, Dhami S. Pneumococcal vaccine for asthma. Cochrane Database Syst Rev 2002;(1):CD002165. Doi: 10.1002/14651858.CD002165.
Bhavsar A, Aris E, Harrington L et al. Burden of Pertussis in Individuals with a Diagnosis of Asthma: A Retrospective Database Study in England. J Asthma Allergy 2022;15:35–51. Doi: 10.2147/JAA.S335960.
Pesek R, Lockey R. Vaccination of adults with asthma and COPD. Allergy 2011;66(1):25–31. Doi: 10.1111/j.1398-9995.2010.02462.x.
The American Lung Association. Good Asthma Management Includes Protecting Against Pertussis [Internet]. 2022 [Consultado 4 jul 2024]. Disponible en: https://www.lung.org/blog/asthma-management-pertussis
Villar-Álvarez F, González-Barcala F-J, Bernal-González PJ. Pertussis vaccine in COPD and asthma: an old acquaintance is back. Open Respiratory Archives 2022;4(1):100153.
Bossios A, Bacon AM, Eger K et al. COVID-19 vaccination acceptance, safety and side-effects in European patients with severe asthma. ERJ Open Res 2023;9(6)::00590-2023. Doi: 10.1183/23120541.00590-2023.
Liang Y, Sun Y. Awareness of and attitude toward COVID-19 vaccination among individuals with COPD and the strategies to overcome vaccine hesitation: A mini review. Hum Vaccin Immunother 2023;19(3):2286686.
Caminati M, Guarnieri G, Batani V, Scarpieri E, Finocchiaro A, Chieco-Bianchi F, et al. COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control. Vaccines (Basel) 2021;9(8):853. Doi: 10.3390/vaccines9080853
Sgalla G, Magrì T, Lerede M, Comes A, Richeldi L. COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2022;206(2):219–21. Doi: 10.1164/rccm.202112-2765LE.